Genmab's Arzerra misses in Phase III for indolent NHL

By Brian Moy | May 25, 2018 | 5:02 PM GMT

Genmab A/S (CSE:GEN) said Arzerra ofatumumab plus Treanda bendamustine missed the primary endpoint of improving progression-free